Stock LIFE PHARMSYNTHEZ
Add to a list
To use this feature you must be a member
Log inSign up

Financials Pharmsynthez

Equities

LIFE

RU000A0JR514

Pharmaceuticals

End-of-day quote Moscow Micex - RTS
Other stock markets
 03:30:00 08/07/2022 am IST 		5-day change 1st Jan Change
4.505 RUB +10.15% Intraday chart for Pharmsynthez -.--% -.--%
2023 Public Joint-Stock Company "Pharmsynthez" Auditor Raises 'Going Concern' Doubt CI
2023 Public Joint-Stock Company "Pharmsynthez" Reports Earnings Results for the Full Year Ended December 31, 2022 CI

Valuation

Fiscal Period: December 2017 2018 2019 2020 2021 2022
Capitalization 1 3,612 1,680 1,249 2,062 1,689 1,356
Enterprise Value (EV) 1 3,465 2,012 1,623 2,675 2,382 2,092
P/E ratio -1.31 x -4.01 x -0.69 x -3.93 x -2.42 x -6.53 x
Yield - - - - - -
Capitalization / Revenue 4.99 x 4.81 x 4.29 x 5.55 x 3.85 x 3.57 x
EV / Revenue 4.79 x 5.76 x 5.58 x 7.2 x 5.43 x 5.51 x
EV / EBITDA -3.59 x -15.2 x -8.46 x -26 x -12.2 x -19.7 x
EV / FCF -60.6 x -43.1 x -25 x -7.91 x 26.9 x 99.7 x
FCF Yield -1.65% -2.32% -4% -12.6% 3.72% 1%
Price to Book 1.71 x 0.48 x 0.92 x 2.03 x 4.89 x 11.2 x
Nbr of stocks (in thousands) 3,01,011 3,01,011 3,01,011 3,01,011 3,01,011 3,01,011
Reference price 2 12.00 5.580 4.150 6.850 5.610 4.505
Announcement Date 27/07/18 01/03/21 01/03/21 30/04/21 28/04/22 19/05/23
1RUB in Million2RUB
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2017 2018 2019 2020 2021 2022
Net sales 1 723.5 349.4 291.1 371.7 438.3 379.7
EBITDA 1 -964.6 -132.4 -191.8 -103 -195.6 -106.1
EBIT 1 -1,015 -187 -217.7 -147.4 -227.6 -126
Operating Margin -140.33% -53.52% -74.8% -39.65% -51.91% -33.18%
Earnings before Tax (EBT) 1 -2,843 -550.7 -2,029 -527.2 -733.4 -208.7
Net income 1 -2,522 -417.7 -1,812 -524.8 -697.6 -207.5
Net margin -348.6% -119.55% -622.45% -141.21% -159.14% -54.65%
EPS 2 -9.134 -1.390 -6.020 -1.744 -2.320 -0.6900
Free Cash Flow 1 -57.23 -46.71 -64.91 -338.3 88.65 20.98
FCF margin -7.91% -13.37% -22.3% -91.03% 20.22% 5.53%
FCF Conversion (EBITDA) - - - - - -
FCF Conversion (Net income) - - - - - -
Dividend per Share - - - - - -
Announcement Date 27/07/18 01/03/21 01/03/21 30/04/21 28/04/22 19/05/23
1RUB in Million2RUB
Estimates

Balance Sheet Analysis

Fiscal Period: December 2017 2018 2019 2020 2021 2022
Net Debt 1 - 333 374 613 693 736
Net Cash position 1 147 - - - - -
Leverage (Debt/EBITDA) - -2.512 x -1.948 x -5.955 x -3.543 x -6.941 x
Free Cash Flow 1 -57.2 -46.7 -64.9 -338 88.6 21
ROE (net income / shareholders' equity) -82% -10.6% -74.9% -44.1% -103% -89%
ROA (Net income/ Total Assets) -13.5% -2.33% -3.9% -4.11% -8.18% -5.7%
Assets 1 18,683 17,948 46,447 12,759 8,529 3,642
Book Value Per Share 2 7.010 11.50 4.530 3.370 1.150 0.4000
Cash Flow per Share 2 1.300 0.0200 0.2200 0.0300 0.0500 0.0300
Capex 1 9.45 19.4 14.5 9.68 0.28 3.47
Capex / Sales 1.31% 5.54% 4.98% 2.61% 0.06% 0.91%
Announcement Date 27/07/18 01/03/21 01/03/21 30/04/21 28/04/22 19/05/23
1RUB in Million2RUB
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Sector Other Pharmaceuticals

1st Jan change Capi.
PHARMSYNTHEZ Stock Pharmsynthez
-.--% 14.93M
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+32.09% 694B
NOVO NORDISK A/S Stock Novo Nordisk A/S
+29.39% 593B
JOHNSON & JOHNSON Stock Johnson & Johnson
-1.34% 371B
MERCK & CO., INC. Stock Merck & Co., Inc.
+20.34% 331B
ABBVIE INC. Stock AbbVie Inc.
+7.39% 290B
ASTRAZENECA PLC Stock AstraZeneca PLC
+14.25% 239B
ROCHE HOLDING AG Stock Roche Holding AG
-3.03% 209B
NOVARTIS AG Stock Novartis AG
+10.02% 209B
AMGEN INC. Stock Amgen Inc.
+8.49% 169B
Other Pharmaceuticals
  1. Stock Market
  2. Equities
  3. LIFE Stock
  4. Financials Pharmsynthez
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
BENEFIT NOW